Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

AC Immune SA (ACIU)

2.42   0.05 (2.11%) 02-07 16:00
Open: 2.4 Pre. Close: 2.37
High: 2.45 Low: 2.35
Volume: 27,067 Market Cap: 202(M)

Technical analysis

as of: 2023-02-07 4:26:11 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 3.02     One year: 3.53
Support: Support1: 2.22    Support2: 2
Resistance: Resistance1: 2.58    Resistance2: 3.02
Pivot: 2.37
Moving Average: MA(5): 2.43     MA(20): 2.36
MA(100): 2.53     MA(250): 3.1
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 60.9     %D(3): 66.6
RSI: RSI(14): 54.9
52-week: High: 4.84  Low: 1.67
Average Vol(K): 3-Month: 205 (K)  10-Days: 233 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ACIU ] has closed below upper band by 36.5%. Bollinger Bands are 49.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.45 - 2.47 2.47 - 2.48
Low: 2.32 - 2.33 2.33 - 2.35
Close: 2.39 - 2.42 2.42 - 2.44

Company Description

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Headline News

Tue, 07 Feb 2023
2023-02-07 | NDAQ:ACIU | Press Release | AC Immune SA - Stockhouse

Sat, 04 Feb 2023
NOLA Gold Rugby picks up win against Dallas Jackals in preseason ... - crescentcitysports.com

Fri, 03 Feb 2023
South Africa: Police Officer in Court for Corruption - AllAfrica - Top Africa News

Thu, 02 Feb 2023
2023-02-02 | NDAQ:ACIU | Press Release | AC Immune SA - Stockhouse

Fri, 27 Jan 2023
ELI LILLY & Updates Holdings in AC Immune (ACIU) - Nasdaq

Thu, 26 Jan 2023
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 83 (M)
% Held by Insiders 3.24e+007 (%)
% Held by Institutions 47.7 (%)
Shares Short 322 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -7.386e+007
EPS Est Next Qtl -0.13
EPS Est This Year -0.63
EPS Est Next Year -0.73
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 923.7
Return on Equity (ttm) -23.2
Qtrly Rev. Growth 3.93e+006
Gross Profit (p.s.) 0
Sales Per Share -70.88
EBITDA (p.s.) -1.11214e+008
Qtrly Earnings Growth -1
Operating Cash Flow 0 (M)
Levered Free Cash Flow -74 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.04
Price to Cash Flow 0.59

Stock Dividends

Dividend 0
Forward Dividend 252210
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.